Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Δ9-tetrahydrocannabinol

Drug and Alcohol Dependence

Volumn 94, Issue 1-3, 2008, Pages 191-198

  Vann, Robert E ^a   Gamage, Thomas F ^a   Warner, Jonathan A ^a   Marshall, Ericka M ^a   Taylor, Nathan L ^a   Martin, Billy R ^a   Wiley, Jenny L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

9 Tetrahydrocannabinol; Cannabidiol; Conditioned place aversion; Drug discrimination; Marijuana

Indexed keywords

CANNABIDIOL; CANNABINOID; DRONABINOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANNABIS ADDICTION; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DYSPHORIA; LONG EVANS RAT; MALE; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL;

ANIMALS; CANNABIDIOL; CANNABIS; CONDITIONING (PSYCHOLOGY); DISCRIMINATION LEARNING; MALE; MICE; MICE, INBRED ICR; SPATIAL BEHAVIOR; TETRAHYDROCANNABINOL;

CANNABIS SATIVA; MUS; RATTUS;

EID: 39149092685     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2007.11.017     Document Type: Article

References (51)

1. Balster R.L., and Prescott W.R. Delta 9-tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci. Biobehav. Rev. 16 (1992) 55-62
2. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J. Ethnopharmacol. 105 (2006) 1-25
3. Berman J.S., Symonds C., and Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain 112 (2004) 299-306
4. Bisogno T., Hanus L., De Petrocellis L., Tchilibon S., Ponde D.E., Brandi I., Moriello A.S., Davis J.B., Mechoulam R., and Di Marzo V. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134 (2001) 845-852
5. Blander A., Hunt T., Blair R., and Amit Z. Conditioned place preference: an evaluation of morphine's positive reinforcing properties. Psychopharmacology (Berl) 84 (1984) 124-127
6. 9-tetrahydrocannabinol. Res. Comm. Chem. Pathol. Pharmacol. 7 (1974) 663-670
7. Bornheim L.M., Everhart E.T., Li J., and Correia M.A. Characterization of cannabidiol-mediated cytochrome P450 inactivation. Biochem. Pharmacol. 45 (1993) 1323-1331
8. Bornheim L.M., Kim K., Beatrice J., Perotti Y., and Benet L. Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab. Dispos. 23 (1995) 825-831
9. Brady C.M., DasGupta R., Dalton C., Wiseman O.J., Berkley K.J., and Fowler C.J. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult. Scler. 10 (2004) 425-433
10. Chaperon F., Soubrie P., Puech A.J., and Thiebot M.H. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology (Berl) 135 (1998) 324-332
11. Cheer J.F., Kendall D.A., and Marsden C.A. Cannabinoid receptors and reward in the rat: a conditioned place preference study. Psychopharmacology (Berl) 151 (2000) 25-30
12. Elsohly M.A., and Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 78 (2005) 539-548
13. 9-THC actions by cannabinol and cannabidiol in the rat. Psychopharmacology 38 (1974) 329-338
14. 9-THC) and cannabidiol (CBD) in aggression, muscle control and body temperature experiments in mice. Psychopharmacology 41 (1975) 169-174
15. Haney M. Effects of smoked marijuana in healthy and HIV + marijuana smokers. J. Clin. Pharmacol. 42 (2002) 34S-40S
16. Hiltunen A.J., and Jarbe T.U. Cannabidiol attenuates delta 9-tetrahydrocannabinol-like discriminative stimulus effects of cannabinol. Eur. J. Pharmacol. 125 (1986) 301-304
17. Hiltunen A.J., and Jarbe T.U. Interactions between delta 9-tetrahydrocannabinol and cannabidiol as evaluated by drug discrimination procedures in rats and pigeons. Neuropharmacology 25 (1986) 133-142
18. Hutcheson D.M., Tzavara E.T., Smadja C., Valjent E., Roques B.P., Hanoune J., and Maldonado R. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. Br. J. Pharmacol. 125 (1998) 1567-1577
19. Jarbe T.U., Henriksson B.G., and Ohlin G.C. Delta9-THC as a discriminative cue in pigeons: effects of delta8-THC, CBD, and CBN. Archives Internationales de Pharmacodynamie et de Therapie 228 (1977) 68-72
20. Jarbe T.U., Hiltunen A.J., Lander N., and Mechoulam R. Cannabimimetic activity (delta 1-THC cue) of cannabidiol monomethyl ether and two stereoisomeric hexahydrocannabinols in rats and pigeons. Pharmacol. Biochem. Behav. 25 (1986) 393-399
21. Jones G., and Pertwee R.G. A metabolic interaction in vivo between cannabidiol and 1-tetrahydrocannabinol. Br. J. Pharmacol. 45 (1972) 375-377
22. 9-tetrahydrocannabinol. Psychopharmacology 33 (1973) 53-70
23. Lepore M., Vorel S.R., Lowinson J., and Gardner E.L. Conditioned place preference induced by delta 9-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward. Life Sci. 56 (1995) 2073-2080
24. Levy S., and McCallum N.K. Cannabidiol and its pharmacokinetic interaction with delta1-tetrahydrocannabinol. Experientia 31 (1975) 1268-1269
25. Mallet P.E., and Beninger R.J. [Delta]9-Tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance. Life Sci. 62 (1998) 2431-2439
26. Martin B.R., Compton D.R., Thomas B.F., Prescott W.R., Little P.J., Razdan R.K., Johnson M.R., Melvin L.S., Mechoulam R., and Ward S.J. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 40 (1991) 471-478
27. McGregor I.S., Issakidis C.N., and Prior G. Aversive effects of the synthetic cannabinoid CP 55, 940 in rats. Pharmacol. Biochem. Behav. 53 (1996) 657-664
28. Parker L.A., Burton P., Sorge R.E., Yakiwchuk C., and Mechoulam R. Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology (Berl) 175 (2004) 360-366
29. Parker L.A., and Gillies T. THC-induced place and taste aversions in Lewis and Sprague-Dawley rats. Behav. Neurosci. 109 (1995) 71-78
30. 2 receptors. Pharmacol. Ther. 74 (1997) 129-180
31. Robinson L., Hinder L., Pertwee R.G., and Riedel G. Effects of delta9-THC and WIN-55,212-2 on place preference in the water maze in rats. Psychopharmacology (Berl) 166 (2003) 40-50
32. Rog D.J., Nurmikko T.J., Friede T., and Young C.A. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65 (2005) 812-819
33. Russo E.B., Burnett A., Hall B., and Parker K.K. Agonistic Properties of Cannabidiol at 5-HT1a Receptors. Neurochem. Res. 30 (2005) 1037-1043
34. Russo E.B., and McPartland J.M. Cannabis is more than simply ?9-tetrahydrocannabinol. Psychopharmacology 165 (2003) 431-432
35. Sanders J., Jackson D.M., and Starmer G.A. Interactions among the cannabinoids in the antagonism of abdominal constriction response in the mouse. Psychopharmacology 61 (1979) 281-285
36. Sanudo-Pena M.C., Tsou K., Delay E.R., Hohman A.G., Force M., and Walker J.M. Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neurosci. Lett. 223 (1997) 125-128
37. Soria G., Castane A., Berrendero F., Ledent C., Parmentier M., Maldonado R., and Valverde O. Adenosine A2A receptors are involved in physical dependence and place conditioning induced by THC. Eur. J. Neurosci. 20 (2004) 2203-2213
38. Svendsen K.B., Jensen T.S., and Bach F.W. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Brit. Med. J. 329 (2004) 253-260
39. Tzschentke T.M. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog. Neurobiol. 56 (1998) 613-672
40. Valjent E., and Maldonado R. A behavioural model to reveal place preference to delta 9-tetrahydrocannabinol in mice. Psychopharmacology (Berl) 147 (2000) 436-438
41. Valjent E., Mitchell J.M., Besson M.J., Caboche J., and Maldonado R. Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. Br. J. Pharmacol. 135 (2002) 564-578
42. Vann R.E., Cook C.D., Martin B.R., and Wiley J.L. Cannabimimetic properties of ajulemic acid. J. Pharmacol. Exp. Ther. 320 (2007) 678-686
43. Varvel S.A., Wiley J.L., Yang R., Bridgen D.T., Long K., Lichtman A.H., and Martin B.R. Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology (Berl) 186 (2006) 226-234
44. Wade D.T., Makela P., Robson P., House H., and Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler. 10 (2004) 434-441
45. Wade D.T., Robson P., House H., Makela P., and Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil. 17 (2003) 21-29
46. Watanabe K., Kayano Y., Matsunaga T., Yamamoto I., and Yoshimura H. Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. Biol. Pharm. Bull. 19 (1996) 1109-1111
47. Welburn P.J., Starmer G.A., Chesher G.B., and Jackson D.M. Effect of cannabinoids on the abdominal constriction response in mice: within cannabinoid interactions. Psychopharmacologia 46 (1976) 83-85
48. Wiley J.L. Cannabis: discrimination of "internal bliss"?. Pharmacol. Biochem. Behav. 64 (1999) 257-260
49. Wiley J.L., Lowe J.A., Balster R.L., and Martin B.R. Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys. J. Pharmacol. Exp. Ther. 275 (1995) 1-6
50. Wiley J.L., and Martin B.R. Cannabinoid pharmacological properties common to other centrally acting drugs. Eur. J. Pharmacol. 471 (2003) 185-193
51. Zuardi, A.W., Crippa, J.A., Hallak, J.E., Moreira, F.A., Guimaraes, F.S., 2006. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Brazilian Journal of Medical And Biological Research 39, 421-429.